Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
Lymphology ; 51(4): 148-159, 2018.
Article in English | MEDLINE | ID: mdl-31119905

ABSTRACT

Compression therapy plays a pivotal role in the treatment of venous leg ulcers and clinical observations include lymph stasis as contributing to the maintenance of chronic wounds. This finding raises the question whether further improvement in lymph circulation with manual lymph drainage (MLD) as a part of complex decongestive physiotherapy (CDP) can improve ulcer healing. We examined whether CDP improves healing of venous leg ulcers and compared the efficacy of CDP with that of multilayered compression with short-stretch bandages. Eight patients (mean age: 64.8 years, mean ulcer area: 23.07 cm2, duration of ulcers: 25.37 months) were treated with a 5-day-course of CDP and 9 patients (mean age: 70.77 years, mean ulcer area: 21.47 cm2, duration of ulcers: 15.8 months) were included in a 10-day-course of CDP. Control goup consisted of 9 patients (mean age: 56.33 years, mean ulcer area: 13.87 cm2, duration of ulcers: 6.11 months) receiving multilayered compression. Wound surface measurement was carried out on days 5 and 10 and ulcer area reduction rate was calculated as area (initial)-area (final)/time unit. There was no statistical difference between the 5-daycourse of CDP and compression of the same duration regarding ulcer healing (t=-1.62, df=15, p= 0.125). A 10-day-course of CDP significantly increased ulcer healing compared to compression of the same duration (t=-2.42, df=16, p= 0.039). Our preliminary results suggest that MLD as a part of CDP supports healing of venous leg ulcers.


Subject(s)
Compression Bandages , Manual Lymphatic Drainage/methods , Varicose Ulcer/therapy , Wound Healing , Adult , Aged , Aged, 80 and over , Case-Control Studies , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pilot Projects , Prognosis , Prospective Studies
2.
Clin Pharmacol Ther ; 103(3): 511-520, 2018 03.
Article in English | MEDLINE | ID: mdl-28643328

ABSTRACT

As drug development is extremely expensive, the identification of novel indications for in-market drugs is financially attractive. Multiple algorithms are used to support such drug repurposing, but highly reliable methods combining simulation of intracellular networks and machine learning are currently not available. We developed an algorithm that simulates drug effects on the flow of information through protein-protein interaction networks, and used support vector machine to identify potentially effective drugs in our model disease, psoriasis. Using this method, we screened about 1,500 marketed and investigational substances, identified 51 drugs that were potentially effective, and selected three of them for experimental confirmation. All drugs inhibited tumor necrosis factor alpha-induced nuclear factor kappa B activity in vitro, suggesting they might be effective for treating psoriasis in humans. Additionally, these drugs significantly inhibited imiquimod-induced ear thickening and inflammation in the mouse model of the disease. All results suggest high prediction performance for the algorithm.


Subject(s)
Drug Repositioning/methods , Gene Regulatory Networks/genetics , Protein Interaction Domains and Motifs , Protein Interaction Maps , Algorithms , Animals , Cell Line , Computer Simulation , Dermatitis/drug therapy , Drug Evaluation, Preclinical , Ear, External/pathology , Humans , Imiquimod , Machine Learning , Mice , Mice, Inbred BALB C , NF-kappa B/drug effects , Psoriasis/chemically induced , Psoriasis/drug therapy , RNA/biosynthesis , RNA/genetics , Support Vector Machine , Tumor Necrosis Factor-alpha/antagonists & inhibitors
3.
J Eur Acad Dermatol Venereol ; 30(9): 1480-90, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27177989

ABSTRACT

BACKGROUND: Many current guidelines provide detailed evidence-based recommendations for acne treatment. OBJECTIVE: To create consensus-based, simple, easy-to-use algorithms for clinical acne treatment in daily office-based practice and to provide checklists to assist in determining why a patient may not have responded to treatment and what action to take. METHODS: Existing treatment guidelines and consensus papers were reviewed. The information in them was extracted and simplified according to daily clinical practice needs using a consensus-based approach and based on the authors' clinical expertise. RESULTS: As outcomes, separate simple algorithms are presented for the treatment of predominant comedonal, predominant papulopustular and nodular/conglobate acne. Patients with predominant comedonal acne should initially be treated with a topical retinoid, azelaic acid or salicylic acid. Fixed combination topicals are recommended for patients with predominant papulopustular acne with treatment tailored according to the severity of disease. Treatment recommendations for nodular/conglobate acne include oral isotretinoin or fixed combinations plus oral antibiotics in men, and these options may be supplemented with oral anti-androgenic hormonal therapy in women. Further decisions regarding treatment responses should be evaluated 8 weeks after treatment initiation in patients with predominant comedonal or papulopustular acne and 12 weeks after in those with nodular/conglobate acne. Maintenance therapy with a topical retinoid or azelaic acid should be commenced once a patient is clear or almost clear of their acne to prevent the disease from recurring. The principal explanations for lack of treatment response fall into 5 main categories: disease progression, non-drug-related reasons, drug-related reasons, poor adherence, and adverse events. CONCLUSION: This practical guide provides dermatologists with treatment algorithms adapted to different clinical features of acne which are simple and easy to use in daily clinical practice. The checklists to establish the causes for a lack of treatment response and subsequent action to take will facilitate successful acne management.


Subject(s)
Acne Vulgaris/therapy , Dermatologic Agents/therapeutic use , Practice Guidelines as Topic , Algorithms , Consensus , Humans
4.
J Eur Acad Dermatol Venereol ; 29(12): 2333-41, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26370610

ABSTRACT

BACKGROUND: Glycerol is known to possess anti-irritant and hydrating properties and previous studies suggested that xylitol may also have similar effects. OBJECTIVE: Our aim was to study whether different concentrations of these polyols restore skin barrier function and soothe inflammation in sodium lauryl sulphate (SLS)-induced acute irritation. METHODS: The experiments were performed on male SKH-1 hairless mice. The skin of the dorsal region was exposed to SLS (5%) for 3 h alone or together with 5% or 10% of glycerol respectively. Further two groups received xylitol solutions (8.26% and 16.52% respectively) using the same osmolarities, which were equivalent to those of the glycerol treatments. The control group was treated with purified water. Transepidermal water loss (TEWL) and skin hydration were determined. Microcirculatory parameters of inflammation were observed by means of intravital videomicroscopy (IVM). Furthermore, accumulation of neutrophil granulocytes and lymphocytes, the expression of inflammatory cytokines and SLS penetration were assessed, as well. RESULTS: Treatment with the 10% of glycerol and both concentrations of xylitol inhibited the SLS-induced elevation of TEWL and moderated the irritant-induced increase in dermal blood flow and in the number of leucocyte-endothelial interactions. All concentrations of the applied polyols improved hydration and prevented the accumulation of lymphocytes near the treatment site. At the mRNA level, neither glycerol nor xylitol influenced the expression of interleukin-1 alpha. However, expression of interleukin-1 beta was significantly decreased by the 10% glycerol treatment, while expression of tumour necrosis factor-alpha decreased upon the same treatment, as well as in response to xylitol. Higher polyol treatments decreased the SLS penetration to the deeper layers of the stratum corneum. CONCLUSION: Both of the analysed polyols exert considerable anti-irritant and anti-inflammatory properties, but the effective concentration of xylitol is lower than that of glycerol.


Subject(s)
Dermatitis, Irritant/drug therapy , Emollients/therapeutic use , Glycerol/therapeutic use , Skin Physiological Phenomena/drug effects , Skin/metabolism , Xylitol/therapeutic use , Animals , Dermatitis, Irritant/etiology , Dermatitis, Irritant/pathology , Emollients/pharmacology , Gene Expression/drug effects , Glycerol/pharmacology , Interleukin-1alpha/genetics , Interleukin-1beta/genetics , Intravital Microscopy , Male , Mice , Mice, Hairless , Permeability/drug effects , Regional Blood Flow/drug effects , Skin/blood supply , Skin/chemistry , Sodium Dodecyl Sulfate/pharmacokinetics , Tumor Necrosis Factor-alpha/genetics , Water/analysis , Water Loss, Insensible/drug effects , Xylitol/pharmacology
5.
J Eur Acad Dermatol Venereol ; 29(2): 224-231, 2015 Feb.
Article in English | MEDLINE | ID: mdl-24731093

ABSTRACT

BACKGROUND: Methotrexate is one the most commonly used systemic therapies for psoriasis. Despite its widespread use in psoriasis therapy, dermatologists' practice regarding the use of methotrexate has not been investigated on global scale. OBJECTIVE: To evaluate the real life use of methotrexate for psoriasis treatment in the dermatological community worldwide. METHODS: A questionnaire consisting of 41 questions was designed by the Psoriasis International Network (PIN). Questions focused on safety, dosing, administration, folic acid supplementation and combination therapy aspects of methotrexate use. The anonymous web-based survey was distributed to dermatologists by the national coordinators of PIN. RESULTS: Between 2 April and 7 August 2012, 481 dermatologists from 63 countries completed the questionnaire. Most respondents were from European and South American countries, whereas the response rate from Central America and the Near East was lowest. The majority of responders were experienced dermatologists (86% had more than 5 years of experience in psoriasis treatment). Starting and maintenance doses of 10 mg of methotrexate or lower were reported by 67% and 42% of respondents respectively. Thirty-eight per cent of respondents stop treatment at a cumulative dose of 2 g, whereas 36% did not consider cumulative dose important in this respect. The primary mode of administration was oral, and the majority of respondents administer folic acid supplementation. Almost all respondents monitored full blood count, liver and renal function tests, whereas procollagen 3 amino terminal peptide measurement and transient elastography is used by only a minority of dermatologists. There were significant differences concerning the doses, routes of administration and safety monitoring among the clinical practices in different geographical locations. CONCLUSION: Current clinical practice of methotrexate use in psoriasis is not uniform, depends on geographical location, and is not in full agreement with clinical guidelines.


Subject(s)
Dermatology/methods , Methotrexate/therapeutic use , Practice Patterns, Physicians' , Psoriasis/drug therapy , Adult , Aged , Aged, 80 and over , Contraindications , Female , Humans , Male , Methotrexate/adverse effects , Middle Aged , Practice Patterns, Physicians'/statistics & numerical data , Surveys and Questionnaires
6.
Br J Dermatol ; 169(2): 243-9, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23521230

ABSTRACT

Blue-light phototherapy has been an essential therapeutic tool in the management of neonatal jaundice for decades. Rarely, it is accompanied by acute dermatological and systemic side-effects, but fortunately these are reversible and can be adequately and promptly treated in routine neonatal practice. In contrast, much less is known about the potential long-term side-effects of neonatal blue-light phototherapy (NBLP). Many of the data that are currently available on how NBLP influences melanocytic naevus (MN) development are controversial. The results of recent well-designed epidemiological surveys suggest that NBLP could well be a risk factor for MN formation, and highlight the need for additional in vivo and in vitro studies. NBLP is at present the mainstay of treatment for neonatal jaundice, but in the future greater consideration should be given to its long-term side-effects when phototherapy is indicated. It is relevant to emphasize the importance of appropriately restricted and adequate clinical guidelines, and strict monitoring of the management of hyperbilirubinaemia, in order to avoid the unnecessary overtreatment of newborn infants.


Subject(s)
Jaundice, Neonatal/therapy , Phototherapy/adverse effects , Eye/radiation effects , Humans , Infant, Newborn , Neoplasms, Radiation-Induced/etiology , Nevus, Pigmented/etiology , Phototherapy/methods , Radiation Dosage , Radiation Injuries/etiology , Skin Neoplasms/etiology
7.
Lymphology ; 44(4): 178-82, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22458119

ABSTRACT

Lipedema is a disproportional obesity featuring light pressure-induced or spontaneous pain. On the basis of our clinical observations, lymphedema therapy, as practiced in our clinic, reduces the perception of pain beyond leg volume reduction. We therefore aimed to measure pain intensity prior and subsequent to treatment. 38 women with lipedema were enrolled in the study with 19 patients undergoing treatment and 19 serving as the control group using exclusively moisturizers. Treatment consisted of once daily manual lymph drainage (MLD), intermittent pneumatic compression (IPC), and multilayered short-stretch bandaging performed throughout a 5-day-course. Pain was evaluated with a 10-item questionnaire, a pain rating scale (PRS), and the Wong-Baker Faces scale. Treatment resulted in a significant reduction of pain with a decrease in mean scores of all three measures. In the control group, only PRS showed significant decrease. Our study results indicate that this treatment regimen not only reduces leg volume and capillary fragility, but also improves pain intensity in patients with lipedema.


Subject(s)
Edema/physiopathology , Lymphedema/therapy , Obesity/physiopathology , Pain/prevention & control , Adult , Aged , Aged, 80 and over , Female , Humans , Leg , Lymphedema/complications , Middle Aged , Pain/etiology , Pain Measurement , Subcutaneous Fat/pathology
8.
Br J Dermatol ; 163(1): 167-73, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20302573

ABSTRACT

BACKGROUND: One of the major technological breakthroughs in the last decade is represented by the diversified medical applications of light-emitting diodes (LEDs). LEDs emitting in the ultraviolet (UV) B spectrum might serve as a more convenient alternative for targeted delivery of phototherapy in inflammatory skin diseases such as psoriasis. OBJECTIVES: We investigated the efficacy and safety of a new UVB-LED phototherapeutic device in chronic plaque-type psoriasis. METHODS: Twenty patients with stable plaque-type psoriasis were enrolled into a prospective, right-left comparative, open study. Symmetrical lesions located on extremities or trunk were chosen; one lesion was treated with the study device, whereas the other lesion served as an untreated control. Two treatment regimens were used in the study, one with an aggressive dose escalation similar to those used for outpatient treatment and one with slow increase in dose, similar to those used for treatment at home. RESULTS: Patients in both groups responded rapidly to the UVB-LED therapy. Early disease resolution was observed in 11 patients (seven in the first group and four in the second group). Overall improvement at end of therapy was 93% in the high-dose group and 84% in the low-dose group. Four patients from the high-dose group and five from the low-dose group were still in remission at the 6-month follow-up visit. CONCLUSIONS: These results suggest that this innovative UVB-LED device is effective in the treatment of localized psoriasis and may be useful in other UV-responsive skin diseases.


Subject(s)
Psoriasis/radiotherapy , Ultraviolet Therapy/methods , Adult , Aged , Female , Humans , Male , Middle Aged , Prospective Studies , Psoriasis/pathology , Radiation Dosage , Severity of Illness Index , Treatment Outcome
9.
J Eur Acad Dermatol Venereol ; 23 Suppl 2: 1-70, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19712190

ABSTRACT

Of the 131 studies on monotherapy or combination therapy assessed, 56 studies on the different forms of phototherapy fulfilled the criteria for inclusion in the guidelines. Approximately three-quarters of all patients treated with phototherapy attained at least a PASI 75 response after 4 to 6 weeks, and clearance was frequently achieved (levels of evidence 2 and 3). Phototherapy represents a safe and very effective treatment option for moderate to severe forms of psoriasis vulgaris. The onset of clinical effects occurs within 2 weeks. Of the unwanted side effects, UV erythema from overexposure is by far the most common and is observed frequently. With repeated or long-term use, the consequences of high, cumulative UV doses (such as premature aging of the skin) must be taken into consideration. In addition, carcinogenic risk is associated with oral PUVA and is probable for local PUVA and UVB. The practicability of the therapy is limited by spatial, financial, human, and time constraints on the part of the physician, as well as by the amount of time required by the patient. From the perspective of the cost-bearing institution, phototherapy has a good cost-benefit ratio. However, the potentially significant costs for, and time required of, the patient must be considered.


Subject(s)
Psoriasis/drug therapy , Adalimumab , Alefacept , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Cyclosporine/adverse effects , Cyclosporine/therapeutic use , Dermatologic Agents/adverse effects , Dermatologic Agents/therapeutic use , Etanercept , Humans , Immunoglobulin G/adverse effects , Immunoglobulin G/therapeutic use , Infliximab , Methotrexate/adverse effects , Methotrexate/therapeutic use , PUVA Therapy/adverse effects , Receptors, Tumor Necrosis Factor/therapeutic use , Recombinant Fusion Proteins/adverse effects , Recombinant Fusion Proteins/therapeutic use , Retinoids/adverse effects , Retinoids/therapeutic use
10.
Lymphology ; 42(4): 188-94, 2009 Dec.
Article in English | MEDLINE | ID: mdl-20218087

ABSTRACT

The application of intermittent pneumatic compression (IPC) as a part of complex decongestive physiotherapy (CDP) remains controversial. The aim of this study was to investigate whether the combination of IPC with manual lymph drainage (MLD) could improve CDP treatment outcomes in women with secondary lymphedema after breast cancer treatment. A randomized study was undertaken with 13 subjects receiving MLD (60 min) and 14 receiving MLD (30 min) plus IPC (30 min) followed by standardized components of CDP including multilayered compression bandaging, physical exercise, and skin care 10 times in a 2-week-period. Efficacy of treatment was evaluated by limb volume reduction and a subjective symptom questionnaire at end of the treatment, and one and two months after beginning treatment. The two groups had similar demographic and clinical characteristics. Mean reductions in limb volumes for each group at the end of therapy, and at one and two months were 7.93% and 3.06%, 9.02% and 2.9%, and 9.62% and 3.6%, respectively (p < 0.05 from baseline for each group and also between groups at each measurement). Although a significant decrease in the subjective symptom survey was found for both groups compared to baseline, no significant difference between the groups was found at any time point. The application of IPC with MLD provides a synergistic enhancement of the effect of CDP in arm volume reduction.


Subject(s)
Breast Neoplasms/complications , Exercise Therapy , Intermittent Claudication/therapy , Intermittent Pneumatic Compression Devices , Lymphedema/therapy , Antineoplastic Agents/adverse effects , Arm/surgery , Breast Neoplasms/therapy , Drainage , Female , Humans , Leg/surgery , Lymphedema/etiology , Middle Aged , Postoperative Complications/prevention & control , Prognosis , Radiotherapy, Adjuvant/adverse effects , Treatment Outcome
11.
Lymphology ; 41(1): 40-4, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18581957

ABSTRACT

Lipedema is a disproportional obesity for which evidence-based treatment is not currently available. We studied whether complete decongestive physiotherapy (CDP) alone or combined with intermittent pneumatic compression (IPC) could improve the treatment outcome in women with lipedema using a prospective, randomized trial. Eleven patients received CDP (60 min) and thirteen CDP (30 min) plus IPC (30 min) once daily in a 5-day-course. Subsequent to drainage, all subjects received multilayered compression bandaging, physical exercise and skin care. Treatment efficacy was evaluated by limb volume reduction. Both groups achieved significant reductions in mean lower extremity volume (p < 0.05). The addition of IPC is safe, although it provides no synergistic benefit to CDP in leg volume reduction under these study conditions.


Subject(s)
Lymphedema/therapy , Physical Therapy Modalities , Adult , Aged , Aged, 80 and over , Female , Humans , Lymphedema/pathology , Massage/methods , Middle Aged , Pilot Projects , Prospective Studies , Skin Care/methods , Treatment Outcome
12.
Lymphology ; 41(4): 161-6, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19306662

ABSTRACT

Lipedema is a disproportional obesity featuring frequent hematoma formation due to even minor traumatic injuries. On the basis of clinical observations, complete decongestive physiotherapy diminishes the incidence of hematomas due to minor injuries beyond leg volume reduction. Hematoma development may be caused by altered capillary resistance (CR) or altered capillary fragility (CF). We measured capillary fragility (CF) before and after complex decongestive physiotherapy (CDP) to examine, whether CDP could reduce CF. 38 women with lipedema were included in the study. Twenty-one (21) patients were treated with CDP and 17 using exclusively moisturizers as the control group. CDP comprised once daily manual lymph drainage, intermittent pneumatic compression and multilayered short-stretch bandaging performed throughout a 5-day-course. CF was evaluated with the vacuum suction method (VSM) using Parrot's angiosterrometer in both groups. Decongestive therapy resulted in a significant reduction of the number of petechiae while no change was detected within the control group. Complete decongestive physiotherapy significantly reduced CF in patients with lipedema and this reduction may lead to reduced hematoma formation.


Subject(s)
Adipose Tissue , Capillary Fragility/physiology , Edema/therapy , Physical Therapy Modalities , Adipose Tissue/pathology , Adult , Aged , Edema/physiopathology , Female , Humans , Massage , Middle Aged
13.
Lymphology ; 40(3): 138-42, 2007 Sep.
Article in English | MEDLINE | ID: mdl-18062616

ABSTRACT

The removal of wisdom teeth is often associated with severe postoperative edema and pain, and operation on the third molar can cause local inflammation that impairs lymph transport. The objective of the study was to assess the efficacy of manual lymph drainage (MLD) in reducing swelling following bilateral wisdom tooth removal. Ten consecutive patients with bilateral impacted wisdom teeth that required surgical removal were enrolled in the study. Each patient was postoperatively treated with MLD (after Vodder's method) on one side of the neck region with the untreated contralateral side as a control. Swelling was evaluated using a tape-measure placed in contact with the skin. The six landmarks of measurement included tragus-lip junction, tragus-pogonion, mandibular angle-external corner of eye, mandibular angle-ala nasi, mandibular angle-lip junction, and mandibular angle-median point of chin. Subjective assessment of MLD was conducted with self-evaluation using a visual analogue bar scale (VAS, range 0-100 mm). Of the 6 linear measurements, 4 lines (2, 4, 5, 6) showed a significant reduction of swelling on the side of MLD compared to the untreated side. Mean score of VAS of pretreatment condition was 35.5 +/- 20.60 mm that decreased to 22 +/- 19.32 mm measured after MLD (p=0.0295). This initial study demonstrates that MLD may promote an improvement of lymph circulation and work in an adjunctive role for reduction of postoperative swelling and pain following removal of impacted third molars.


Subject(s)
Drainage/methods , Edema/prevention & control , Lymph , Molar, Third/surgery , Pain, Postoperative/prevention & control , Adolescent , Adult , Edema/etiology , Face , Female , Humans , Male , Pain, Postoperative/etiology , Postoperative Care/methods , Postoperative Period , Tooth Extraction/adverse effects , Tooth, Impacted/surgery , Treatment Outcome
14.
J Photochem Photobiol B ; 89(2-3): 163-9, 2007 Dec 14.
Article in English | MEDLINE | ID: mdl-17997323

ABSTRACT

RATIONALE: Rhinophototherapy has been shown to be effective in the treatment of allergic rhinitis. Considering that phototherapy with ultraviolet light (UV) induces DNA damage, it is of outstanding importance to evaluate the damage and repair process in human nasal mucosa. METHODS: We have investigated eight patients undergoing intranasal phototherapy using a modified Comet assay technique and by staining nasal cytology samples for cyclobutane pyrimidine dimers (CPDs), which are UV specific photoproducts. RESULTS: Immediately after last treatment Comet assay of nasal cytology samples showed a significant increase in DNA damage compared to baseline. Ten days after the last irradiation a significant decrease in DNA damage was observed compared to data obtained immediately after finishing the treatment protocol. Difference between baseline and 10 days after last treatment was not statistically significant. Two months after ending therapy, DNA damage detected by Comet assay in patients treated with intranasal phototherapy was similar with that of healthy individuals. None of the samples collected before starting intranasal phototherapy stained positive for CPDs. In all samples collected immediately after last treatment strong positive staining for CPDs was detected. The number of positive cells significantly decreased 10 days after last treatment, but residual positive staining was present in all the examined samples. This finding is consistent with data reported in skin samples after UV irradiation. Cytology samples examined two months after ending therapy contained no CPD positive cells. CONCLUSION: Our results suggest that UV damage induced by intranasal phototherapy is efficiently repaired in nasal mucosa.


Subject(s)
Nasal Mucosa/radiation effects , Phototherapy/adverse effects , Rhinitis, Allergic, Seasonal/radiotherapy , Ultraviolet Rays/adverse effects , Cells, Cultured , Comet Assay , DNA Damage , DNA Repair , Epithelial Cells/radiation effects , Humans , Nasal Mucosa/chemistry , Nasal Mucosa/pathology , Pyrimidine Dimers/analysis
15.
J Eur Acad Dermatol Venereol ; 20(6): 657-60, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16836491

ABSTRACT

BACKGROUND: Narrow-band ultraviolet B phototherapy is an effictive and safe treatment for atopic dermatitis. We have previously found that the 308 nm xenon chloride excimer laser was more effective than the narrow-band ultraviolet B light for the treatment of psoriasis, suggesting that ultraviolet B laser might offer advantages over narrow-band ultraviolet B. OBJECTIVE: The purpose of this study was to evaluate the therapeutic efficacy of the 308 nm excimer laser in atopic dermatitis. PATIENTS AND METHODS: Fifteen patients with atopic dermatitis (less than 20% body area involvement) were treated with a xenon chloride excimer laser (XTRAC laser, Photomedex Inc.) twice weekly. The severity of the atopic dermatitis was assessed via (i) a clinical score characterizing the intensity of erythema, infiltration, lichenification and excoriation; (ii) the quality of life, determined by means of a questionnaire; and (iii) a visual linear analogue scale, with which the patients scored the severity of their pruritus. RESULTS: After 1 month of laser therapy, the clinical scores were significantly lower than the initial values. Similar decreases were observed for the quality of life and pruritus scores. No serious or unpleasant side-effects were observed. CONCLUSION: These results suggest that the xenon chloride excimer laser is an effective and well-tolerated treatment for localized atopic dermatitis.


Subject(s)
Chlorides , Dermatitis, Atopic/therapy , Laser Therapy/methods , Xenon , Adolescent , Adult , Dermatitis, Atopic/pathology , Female , Humans , Laser Therapy/adverse effects , Male , Quality of Life , Severity of Illness Index , Surveys and Questionnaires , Treatment Outcome
16.
Br J Dermatol ; 146(5): 764-9, 2002 May.
Article in English | MEDLINE | ID: mdl-12000371

ABSTRACT

BACKGROUND: It is well known from clinical practice that repeated treatment with dithranol leads to the development of tolerance. OBJECTIVES: To investigate the characteristics and mechanism of such dithranol tolerance. METHODS: The mouse ear was pretreated with a low dose of dithranol or croton oil or, in previously sensitized animals, with dinitrofluorobenzene (DNFB). Twenty-four hours later irritant dermatitis was elicited by painting the mouse ear with a high dose of dithranol, croton oil or DNFB, and the dermatitis was characterized by measurement of ear thickness. RESULTS: Low-dose dithranol significantly suppressed dithranol-induced oedema, whereas it had no effect on croton oil- or DNFB-induced dermatitis, suggesting that dithranol-induced tolerance is specific. Tolerance to dithranol could not be induced by pretreatment of the mouse ear with a low dose of croton oil or DNFB. Mild tape stripping of the mouse ear also inhibited the inflammatory effect of dithranol applied 24 h later. Superoxide dismutase treatment abolished the tolerance-inducing effect of low-dose dithranol or stripping. CONCLUSIONS: These results suggest that superoxide anion radicals are involved not only in the inflammatory effect of dithranol, but also in the induction of tolerance.


Subject(s)
Anthralin/toxicity , Anti-Inflammatory Agents/toxicity , Drug Eruptions/prevention & control , Ear Diseases/chemically induced , Edema/chemically induced , Administration, Topical , Animals , Anthralin/administration & dosage , Anti-Inflammatory Agents/administration & dosage , Croton Oil/toxicity , Dinitrofluorobenzene/toxicity , Drug Administration Schedule , Drug Tolerance , Ear, External , Male , Mice , Mice, Inbred Strains , Superoxide Dismutase/pharmacology
18.
Am J Vet Res ; 38(9): 1285-8, 1977 Sep.
Article in English | MEDLINE | ID: mdl-921021

ABSTRACT

To ascertain what class of immunoglobulin (Ig; IgA, IgG, or IgM) is most efficacious in protection, a large quantity of colostrum from sows immunized with virulent transmissible gastroenteritis (TGE) virus was fractionated by chromatographic and gel filtration methods. The isolated IgG, IgA, and IgM(A) had specific virus-neutralizing activities of 1:7.6, 1:342, and 1:302 per milligram of protein, respectively. Each Ig was fed to groups of hysterectomy-derived colostrum-deprived neonatal pigs before and after exposure (challenge) with virulent TGE virus. The 7 pigs fed IgG survived the challenge exposure, but 2 of 7 fed IgA and 1 of 7 fed IgM(A) died of TGE. Three of the survivor pigs that had been fed IgG and 2 of the survivor pigs that had been fed IgA had increased serum antibody titers between 8 and 19 days after challenge exposure, but none of the survivor pigs fed IgM(A) had TGE antibody. In contrast, 12 of 14 virus-control pigs died of TGE and the 2 survivors had antibody conversion. The data show that all 3 Ig classes in immune colostrum will protect neonatal pigs against exposure with virulent TGE virus.


Subject(s)
Colostrum/immunology , Gastroenteritis, Transmissible, of Swine/prevention & control , Immunoglobulin A , Immunoglobulin G , Immunoglobulin M , Animals , Animals, Newborn , Antibody Formation , Female , Gastroenteritis, Transmissible, of Swine/immunology , Immunization, Passive , Pregnancy , Swine , Vaccination/veterinary
19.
J Immunol Methods ; 11(3-4): 333-43, 1976.
Article in English | MEDLINE | ID: mdl-180183

ABSTRACT

Similar immunoglobulin (Ig) classes were obtained from porcine colodtral whey by either column or batch chromatographic procedures; a stepwise buffer elution technique was used. Specific transmissible gastroenteritis virus neutralizing antibody was found in the 4 major fractions eluted comprising of IgG1, IgG2, IgA, and IgM. The IgG1, and IgG2 were essentially homogeneous, and the IgA- AND IgM-rich fractions had to be recycled several times through Sephadex G-200 to obtain pure IgA and IgM that had specific virus neutralizing activities per mg of protein of 342.1 and 302. 4, compared with 7.6 for IgG. By a combination of the batch chromatographic procedures and gel filtration, gram amounts of specific Ig could be fractionated from the same colostrum.


Subject(s)
Colostrum/immunology , Coronaviridae/immunology , Immunoglobulin A/isolation & purification , Immunoglobulin G/isolation & purification , Immunoglobulin M/isolation & purification , Transmissible gastroenteritis virus/immunology , Animals , Antibodies, Viral/analysis , Chromatography, DEAE-Cellulose/methods , Chromatography, Gel , Swine
SELECTION OF CITATIONS
SEARCH DETAIL